GliaCure Initiates Phase 1b Dosing in Alzheimer’s Patients
GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced that it has initiated dosing of Alzheimer’s patients in a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a potential disease-modifying treatment. GliaCure’s innovative approach to treating Alzheimer’s disease is innovative in that it both promotes the clearance of amyloid and stimulates anti-inflammatory actions through a single target, an approach that has recently been supported by research studies from independent groups.
“We are optimistic that our Phase 1b study will demonstrate that GC021109 is both safe and well tolerated in early stage Alzheimer’s patients,” stated GliaCure board member Joe Zakrzewski. “Data from this study will prove invaluable as we move forward with the design our Phase 2 trial.”
GliaCure’s Phase 1b trial, which began recruiting volunteers in February 2015, includes multiple ascending dosing of 36 subjects and is intended to demonstrate safety and tolerability of GC021109. The study is co-funded by the Alzheimer’s Drug Discovery Foundation (ADDF). More information about the study can be found at https://clinicaltrials.gov/ct2/show/NCT02386306?term=gliacure&rank=1.